Yunasan Elvina, Ning Xinyuan, Shaik Mohammed Rifat, Pennant Marjorie
Department of Internal Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, Maryland.
Division of Endocrinology, Diabetes, and Nutrition, University of Maryland Medical Center, Baltimore, Maryland.
AACE Clin Case Rep. 2024 Feb 23;10(3):93-96. doi: 10.1016/j.aace.2024.02.006. eCollection 2024 May-Jun.
BACKGROUND/OBJECTIVE: Pheochromocytoma can recur years after curative surgical resection. Rarely, it may reoccur as metastasis. Here, we present a case of metastatic pheochromocytoma to the bones in a patient with neurofibromatosis type 1 (NF1), 8 years after initial resection of primary bilateral adrenal pheochromocytomas without metastases.
A 44-year-old woman presented with diffuse body pain and palpitations. Her past medical history included NF1 and hypertension. Eight years prior to her current presentation, she had undergone a bilateral adrenalectomy for the management of bilateral adrenal pheochromocytomas. Her plasma metanephrines normalized after surgery and remained normal at her 1-year postoperative visit. She was subsequently lost to follow-up until her current presentation. Our evaluation revealed significantly elevated urine and plasma metanephrines as well as innumerable DOTATATE avid lesions along the axial and perpendicular spine compatible with a metastatic neuroendocrine tumor. She was started on doxazosin and metoprolol and discharged home with a plan to be seen by Oncology to discuss systemic therapy.
Predicting malignant disease in patients with primary tumors without metastases is challenging. There is no single factor that can reliably predict tumor behavior. It is unknown if individuals with NF1, who have a genetic predisposition for developing pheochromocytomas, are at an increased risk of malignant disease.
Due to a lack of accurate predictors, annual biochemical testing is recommended after primary tumor resection and in patients with a genetic predisposition. Strict lifelong follow-up should be strongly considered due to a possible higher risk of malignant disease.
背景/目的:嗜铬细胞瘤在根治性手术切除数年后可能复发。极少数情况下,它可能以转移的形式再次出现。在此,我们报告一例1型神经纤维瘤病(NF1)患者,在初次切除原发性双侧肾上腺嗜铬细胞瘤且无转移8年后,发生了骨转移嗜铬细胞瘤。
一名44岁女性出现全身弥漫性疼痛和心悸。她既往有NF1病史和高血压。在此次就诊前8年,她因双侧肾上腺嗜铬细胞瘤接受了双侧肾上腺切除术。术后她的血浆间甲肾上腺素水平恢复正常,术后1年随访时仍保持正常。随后她失访,直至此次就诊。我们的评估显示尿和血浆间甲肾上腺素显著升高,以及沿脊柱轴向和垂直方向有无数与转移性神经内分泌肿瘤相符的DOTATATE摄取阳性病变。她开始服用多沙唑嗪和美托洛尔,出院时计划前往肿瘤科就诊以讨论全身治疗方案。
预测无转移原发性肿瘤患者的恶性疾病具有挑战性。没有单一因素能够可靠地预测肿瘤行为。对于有发生嗜铬细胞瘤遗传易感性的NF1个体是否患恶性疾病风险增加尚不清楚。
由于缺乏准确的预测指标,建议在原发性肿瘤切除后以及有遗传易感性的患者中每年进行生化检测。鉴于可能存在较高的恶性疾病风险,应强烈考虑进行严格的终身随访。